3月10日 - ** 美国制药商礼来LLY.N股价盘前下跌1.5%，至856.37美元
** 丹麦竞争对手诺和诺德NOVOb.CO报告了其下一代减肥实验药物CagriSema的后期数据： (link)
** 称CagriSema在68周后帮助超重的2型糖尿病患者(T2D)，体重减轻了15.7%，而服用安慰剂仅为3.1%。
** 在一项晚期研究中，LLY 的肥胖症药物 Zepbound 对 T2D 患者的治疗在第 68 周时的绝对减重率高达约 15.5% - 经纪公司 Leerink Partners
** 券商称，CagriSema 的减重数据似乎与 LLY 的 Zepbound 的交叉试验具有可比性
** 截至上次收盘，LLY 的股价在过去 12 个月中上涨了 11.5
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.